Addressing Healthcare Disparities and COVID-19 Concerns for All Patients with Multiple Sclerosis


Program Dates: March 9th, 2021 - March 8th, 2022
Credits: 1.25 AMA PRA Category 1 Credits™; 1.25 CNE Contact Hours; 1.25 CPE Contact Hours (0.125 CEUs)


Addressing Healthcare Disparities and COVID-19 Concerns for All Patients with Multiple Sclerosis

Program Overview

This CME/CE symposium, led by Fred D. Lublin, MD, is derived from content presented at the Virtual ACTRIMS Forum in February, 2021. In this program, the expert faculty will review current disparities for the management of patients across the entire spectrum of disease with multiple sclerosis (MS). The faculty will discuss the immune-science relationship between COVID-19 infections and therapeutic options in MS. Additionally, the clinical applications of the latest therapeutic advances in MS, including patients with COVID-19 concerns, will be analyzed. This interactive, educational activity is designed to address the intersection of healthcare disparities, immune-science, and the effects of the COVID-19 pandemic on therapeutic decision-making for all patients with multiple sclerosis.

Target Audience

Neurologists, MS specialists, nurse practitioners, physicians’ assistants, nurses, and pharmacists who comprise the comprehensive MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis

Learning Objectives

  1. Discuss current healthcare disparities for the management of all patients with multiple sclerosis
  2. Analyze the immune-science relationship between COVID-19 infections and therapeutic options in MS
  3. Explore clinical applications of the latest therapeutic advances in MS to manage all patients, including patients with COVID-19 concerns

Agenda

I. Welcome and Introductions – Fred D. Lublin, MD

II. Addressing Current Healthcare Disparities for the Management of All Patients with MS – Sylvia Klineova, MD

III. Clinical Practice Update: The Immune-Science Relationship Between COVID-19 Infections and Therapeutic Options in MS – Aaron Miller, MD

IV. Clinical Applications of the Latest Therapeutic Advances in MS to Manage All Patients, Including COVID-19 Concerns: Interactive Panel Discussion – Fred D. Lublin, MD and All Faculty

Chair

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

Faculty

Sylvia Klineova, MD
Assistant Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

Aaron Miller, MD
Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Fred D. Lublin, MD

 

Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals Ltd; Apitope; Atara Biotherapeutics, Inc.; Avotres Inc.; Biogen; BrainStorm Cell Limited; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Greenwich Biosciences, a GW Pharmaceuticals PLC Company; Immunic Therapeutics; Innate Immunotherapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals, Inc.; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; MedImmune Pharma; Mylan; Novartis AG; Orion Biotechnology; Polpharma; Population Council; Receptos; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Viela Bio

Grant/Research Support:  Actelion Pharmaceuticals Ltd; Biogen; BrainStorm Cell Limited; Novartis AG; Sanofi Genzyme

Speaker’s Bureau: Sanofi Genzyme

 

Sylvia Klineova, MD

 

Consultant/Advisor: Biogen; Genentech, Inc.

Speakers Bureau: Alexion Pharmaceuticals, Inc.; Biogen

Aaron Miller, MD

 

Consultant/Advisor: AbbVie Inc.; Accordant, A CVS Caremark Company; Adamas Pharmaceuticals, Inc.; Biogen; Bristol-Myers Squibb; Celgene Corporation; Corrona, LLC; EMD Serono, Inc.; Genentech, Inc.; Janssen Global Services, LLC; Mapi-Pharma Ltd.; Mylan; Novartis AG; Roche; Verana Health

Grant/Research Support: Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Roche; Sanofi Genzyme

Speakers Bureau: Alexion Pharmaceuticals, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; John Fanikos, RPh; Amy Perrin Ross, APN, MSN, CNRN, MSCN; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.

AcademicCME designates this enduring material for a maximum of 1.25 CNE Contact Hours.

AcademicCME designates this continuing education activity for 1.25 CPE Contact Hours (0.125 CEUs) of continuing pharmacy education credit (JA4008190-0000-21-009-H04-P).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by independent educational grants from Biogen, Bristol-Myers Squibb and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Biogen, Bristol-Myers Squibb and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web